The launch of new biosimilars and an uptick in drugmaker transactions are expected to make waves in the pharmaceutical industry over the coming months, Moody’s Investment Service said in a quarterly healthcare report issued Jan. 24.
Read the full post on Becker's Hospital Review - Healthcare News
